Compare BCS & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCS | ZTS |
|---|---|---|
| Founded | 1690 | 1952 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4B | 66.2B |
| IPO Year | N/A | 2013 |
| Metric | BCS | ZTS |
|---|---|---|
| Price | $23.41 | $120.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $178.89 |
| AVG Volume (30 Days) | ★ 5.6M | 5.1M |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.86% | 1.66% |
| EPS Growth | ★ 45.84 | 11.64 |
| EPS | 0.54 | ★ 5.94 |
| Revenue | ★ $34,970,562,135.00 | $9,397,000,000.00 |
| Revenue This Year | $20.45 | $3.11 |
| Revenue Next Year | $5.12 | $5.14 |
| P/E Ratio | ★ $10.13 | $20.28 |
| Revenue Growth | ★ 10.24 | 2.68 |
| 52 Week Low | $12.14 | $115.25 |
| 52 Week High | $23.57 | $181.85 |
| Indicator | BCS | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 70.41 | 36.18 |
| Support Level | $22.95 | $115.25 |
| Resistance Level | $22.91 | $129.58 |
| Average True Range (ATR) | 0.33 | 3.22 |
| MACD | 0.18 | 0.93 |
| Stochastic Oscillator | 94.32 | 34.93 |
Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.